tetano
Editor, Senior Moderator
Sci Rep
. 2024 May 28;14(1):12176.
doi: 10.1038/s41598-024-63147-z. Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients
Keita Kawashiro[SUP] #[/SUP][SUP] 1 [/SUP], Rigel Suzuki[SUP] #[/SUP][SUP] 2 3 [/SUP], Takuto Nogimori[SUP] #[/SUP][SUP] 4 [/SUP], Shuhei Tsujino[SUP] 2 [/SUP], Naoya Iwahara[SUP] 1 [/SUP], Takayuki Hirose[SUP] 1 [/SUP], Kazufumi Okada[SUP] 5 [/SUP], Takuya Yamamoto[SUP] 6 7 8 [/SUP], Takasuke Fukuhara[SUP] 9 10 11 12 [/SUP], Kiyohiko Hotta[SUP] 13 [/SUP], Nobuo Shinohara[SUP] 1 [/SUP]
Affiliations
Although the mRNA SARS-CoV-2 vaccine has improved the mortality rate in the general population, its efficacy against rapidly mutating virus strains, especially in kidney transplant recipients, remains unclear. We examined the anti-SARS-CoV-2 spike protein IgG antibody and neutralizing antibody titers and cellular immunity against B.1.1, BA.1, and BA.5 antigens in 73 uninfected kidney recipients and 16 uninfected healthy controls who received three doses of an mRNA SARS-CoV-2 vaccine. The IgG antibody titers were significantly lower in recipients than in healthy controls. Similarly, neutralizing antibody titers against three viral variants were significantly lower in recipients. When the virus was mutated, the neutralizing antibody titers decreased significantly in both groups. In cellular immunity analysis, the number of spike-specific CD8 + non-naïve T cells against three variants significantly decreased in recipients. Conversely, the frequency of spike-specific Th2 CD4 + T-cells in recipients was higher than that in healthy controls. Nineteen recipients and six healthy controls also received a bivalent omicron-containing booster vaccine, leading to increase IgG and neutralizing antibody titers in both groups. After that, eleven recipients and five healthy controls received XBB.1.5 monovalent vaccines, increasing the neutralizing antibody titers against not only XBB.1.5, but also EG.5.1 and BA.2.86 antigens in kidney recipients. Although kidney recipients did not gain sufficient immunity against Omicron BA.5 with the third dose of vaccine, humoral response against mutant SARS-CoV-2 lineages significantly increased after bivalent Omicron-containing booster vaccine and the XBB.1.5 monovalent vaccine. Therefore, it is important for kidney recipients to continue to administer updated vaccines.
. 2024 May 28;14(1):12176.
doi: 10.1038/s41598-024-63147-z. Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients
Keita Kawashiro[SUP] #[/SUP][SUP] 1 [/SUP], Rigel Suzuki[SUP] #[/SUP][SUP] 2 3 [/SUP], Takuto Nogimori[SUP] #[/SUP][SUP] 4 [/SUP], Shuhei Tsujino[SUP] 2 [/SUP], Naoya Iwahara[SUP] 1 [/SUP], Takayuki Hirose[SUP] 1 [/SUP], Kazufumi Okada[SUP] 5 [/SUP], Takuya Yamamoto[SUP] 6 7 8 [/SUP], Takasuke Fukuhara[SUP] 9 10 11 12 [/SUP], Kiyohiko Hotta[SUP] 13 [/SUP], Nobuo Shinohara[SUP] 1 [/SUP]
Affiliations
- PMID: 38806644
- PMCID: PMC11133393
- DOI: 10.1038/s41598-024-63147-z
Although the mRNA SARS-CoV-2 vaccine has improved the mortality rate in the general population, its efficacy against rapidly mutating virus strains, especially in kidney transplant recipients, remains unclear. We examined the anti-SARS-CoV-2 spike protein IgG antibody and neutralizing antibody titers and cellular immunity against B.1.1, BA.1, and BA.5 antigens in 73 uninfected kidney recipients and 16 uninfected healthy controls who received three doses of an mRNA SARS-CoV-2 vaccine. The IgG antibody titers were significantly lower in recipients than in healthy controls. Similarly, neutralizing antibody titers against three viral variants were significantly lower in recipients. When the virus was mutated, the neutralizing antibody titers decreased significantly in both groups. In cellular immunity analysis, the number of spike-specific CD8 + non-naïve T cells against three variants significantly decreased in recipients. Conversely, the frequency of spike-specific Th2 CD4 + T-cells in recipients was higher than that in healthy controls. Nineteen recipients and six healthy controls also received a bivalent omicron-containing booster vaccine, leading to increase IgG and neutralizing antibody titers in both groups. After that, eleven recipients and five healthy controls received XBB.1.5 monovalent vaccines, increasing the neutralizing antibody titers against not only XBB.1.5, but also EG.5.1 and BA.2.86 antigens in kidney recipients. Although kidney recipients did not gain sufficient immunity against Omicron BA.5 with the third dose of vaccine, humoral response against mutant SARS-CoV-2 lineages significantly increased after bivalent Omicron-containing booster vaccine and the XBB.1.5 monovalent vaccine. Therefore, it is important for kidney recipients to continue to administer updated vaccines.